SynthesisTechniques in coloproctology2024
Sclerotherapy for hemorrhoidal disease: systematic review and meta-analysis.
Synthesis in Techniques in coloproctology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Clinical outcomes of different sclerosing agents for hemorrhoids: a network meta-analysis.Frontiers in medicine · 2026Pooled it
- Real-world use of polidocanol foam sclerotherapy for hemorrhoidal disease: insights from an international survey and systematic review with clinical practice recommendations.Updates in surgery · 2025Pooled it
- Polidocanol foam sclerotherapy for hemorrhoidal disease in a private outpatient setting: a real-world single-center study combining chart review and WhatsApp-delivered patient-reported outcomes.Updates in surgery · 2026Article
- Polidocanol foam sclerotherapy for patients with Goligher grade IV hemorrhoidal disease unwilling to undergo surgery: preliminary outcomes from a retrospective study with 6-month follow-up.International journal of colorectal disease · 2026Article
- Knowledge, attitudes, and practices of hemorrhoid patients regarding surgical treatment.Scientific reports · 2026Article
- Early hemodynamic changes following endoscopic sclerotherapy for hemorrhoidal disease assessed by transperineal ultrasound and their relationship with clinical outcomes.International journal of colorectal disease · 2026Observational
- Effectiveness and safety of 3% polidocanol foam sclerotherapy in hemorrhoidal disease: a multicenter, prospective study.International journal of colorectal disease · 2026Observational
- Upper border of anal transitional zone: a new landmark for endoscopic internal hemorrhoid therapy.Frontiers in medicine · 2026Article
- Evaluating Turkish society's approaches to hemorrhoid treatment using text mining and sentiment analysis methods.Frontiers in surgery · 2026Article
- Comparative effectiveness and recurrence rates of endoscopic sclerotherapy, ligation, and combined therapy for grades I-III internal hemorrhoids.BMC surgery · 2025Article
- Indirect assessment of hemorrhoid incidence using invasive treatment data in Japan: A 5-year study based on nationwide health insurance claims.Annals of gastroenterological surgery · 2025Article
- Is Injectable Sclerotherapy with Polidocanol Foam Effective for Treating Hemorrhoids in Patients with Severe Anemia?Journal of the anus, rectum and colon · 2025Article
- Shifting Paradigms in Hemorrhoid Management: The Emergence and Impact of Cap-Assisted Endoscopic Sclerotherapy.Journal of clinical medicine · 2024Review
- Endoscopic polidocanol foam sclerobanding for treatment of internal hemorrhoids: A novel outpatient procedure.World journal of gastroenterology · 2024Article
- Clinical evidence and rationale of mesoglycan to treat chronic venous disease and hemorrhoidal disease: a narrative review.Updates in surgery · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis systematic review and meta-analysis aimed to evaluate the safety and efficacy of sclerotherapy methods for hemorrhoidal disease (HD) over the past 40 years.
methodsThe review followed the 2020 Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. A comprehensive literature search was conducted, including studies reporting the use of sclerotherapy in patients with HD. Study eligibility criteria were defined, and data were extracted independently by the authors. Random-effects meta-analyses were performed to assess outcomes of interest.
resultsOut of 1965 records identified, 44 studies met the inclusion criteria, involving 9729 patients. The majority of studies were conducted in Japan, followed by the UK, Italy, and Portugal. The median age of participants was 52 years, and the majority were male. The Goligher grade distribution indicated varying degrees of HD severity. Sclerotherapy was predominantly administered through anoscopy, with polidocanol being the most commonly used agent. The procedure was generally performed without pre-injection analgesia. The meta-analysis of 14 randomized controlled trials (RCTs) revealed that sclerotherapy was not inferior to control interventions in terms of success rate (risk ratio [RR] 1.00, 95% CI 0.71-1.41) and recurrence rate (RR 1.11, 95% CI 0.69-1.77), while resulting in fewer complications (RR 0.46, 95% CI 0.23-0.92).
conclusionsThis systematic review highlights the safety and efficacy of sclerotherapy for HD, which yields similar success rates and fewer complications compared to other conservative or surgical approaches. Further research is warranted to optimize sclerotherapy techniques and evaluate long-term outcomes. REGISTRATION: PROSPERO 2023 CRD42023396910.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.